1360734-87-7

Upstream product

• 100-39-0 benzyl bromide 
• 778591-56-3 (6R,12bS)-1,2,3,6,7,12b-hexahydro-6-(hydroxymethyl)indolo[2,3-a]quinolizin-4(12H)-one 

Downstream Products

• 1360734-96-8 C₂₄H₂₈N₂O 
• 1360734-97-9 (6R)-6-(allyloxymethyl)-12-benzyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizine 
• 1360734-98-0 (2R,6R)-6-(allyloxymethyl)-12-benzyl-2-vinyl-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-4(12H)-one 
• 1360734-99-1 (6R)-6-(allyloxymethyl)-12-benzyl-1,6,7,12b-tetrahydroindolo[2,3-a]quinolizin-4(12H)-one 
• 1360735-01-8 C₃₂H₃₂N₂O₂Se 
• 1360734-90-2 (6R)-6-(allyloxymethyl)-12-benzyl-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-4(12H)-one 
• 1360734-89-9 (6R)-12-benzyl-6-(methoxymethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-4(12H)-one 
• 1360734-92-4 C₃₀H₃₆N₂O₂ 
• 1360734-91-3 C₂₆H₃₀N₂O₂ 

Relevant academic research and scientific papers

Enantiopure indolo[2,3-a]quinolizidines: Synthesis and evaluation as NMDA receptor antagonists

Enantiopure tryptophanol is easily obtained from the reduction of its parent natural amino acid trypthophan (available from the chiral pool), and can be used as chiral auxiliary/inductor to control the stereochemical course of a diastereoselective reaction. Furthermore, enantiopure tryptophanol is useful for the syntheses of natural products or biological active molecules containing the aminoalcohol functionality. In this communication, we report the development of a small library of indolo[2,3-a]quinolizidines and evaluation of their activity as N-Methyl D-Aspartate (NMDA) receptor antagonists. The indolo[2,3-a]quinolizidine scaffold was obtained using the following key steps: (i) a stereoselective cyclocondensation of (S)- or (R)-tryptophanol with appropriate racemic δ-oxoesters; (ii) a stereocontrolled cyclization on the indole nucleus. The synthesized enantiopure indolo[2,3-a]quinolizidines were evaluated as NMDA receptor antagonists and one compound was identified to be 2.9-fold more potent as NMDA receptor blocker than amantadine (used in the clinic for Parkinson's disease). This compound represents a hit compound for the development of novel NMDA receptor antagonists with potential applications in neurodegenerative disorders associated with overactivation of NMDA receptors.

Synthesis and evaluation of a novel series of indoloisoquinolines as small molecule anti-malarial leads

A group of novel synthetic indoloisoquinolines was prepared and its potential as a novel series of smallmolecule anti-malarial leads was assessed. The structure-activity relationship on variation of three distinct regions of chemical space was investigate